The trial’s results may support earlier use of dual IL-17A/F inhibitors in patients with both skin and joint disease.
Peter Nash, MBBS, FRACP, FQAAS
Advertisement
Peter Nash, MBBS, FRACP, FQAAS is a leading rheumatologist and researcher at the School of Medicine, Griffith University, Brisbane, Australia.
Articles by Peter Nash, MBBS, FRACP, FQAAS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Dermatology Times
1
Dermalogica Enters Medical Aesthetics with FDA-Cleared Microneedling PRO Pen
2
Social Media Mythbusters: Hypochlorous Acid Sprays
3
Quoin Submits First-Ever IND Application for Peeling Skin Syndrome Therapy
4
Topical GX-03 Hits 92.6% EASI-50 at Week 4 in Phase 2 AD Interim
5